Noindex: medium evidence

Ginsenoside Re

CAS 52286-59-6

Ginsenoside Re (CAS 52286-59-6) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Ginsenoside Re
CAS Number
52286-59-6
UNII
46F3R0BL3I
InChIKey
PWAOOJDMFUQOKB-WCZZMFLVSA-N
ChEMBL ID
CHEMBL510095
Molecule Type
Oligosaccharide
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Ginsenoside Re used for in pharmaceutical contexts?

Ginsenoside Re (CAS 52286-59-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Ginsenoside Re?

No adverse-event association or SIDER side-effect rows are rendered for Ginsenoside Re in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Ginsenoside Re also used in cosmetics?

No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Ginsenoside Re.

What clinical phase is Ginsenoside Re in?

No phase 1-4 clinical development badge is rendered for Ginsenoside Re because the matched compound identifier rows do not contain a max-phase value.